With AI-BIO
PIPELINE
Pipeline
Baobab AiBIO Pipeline
Drug Repositioning
New Chemical Entity
Large Molecule
| Status | Program | Target Disease | Exploratory | Research | IND Enabling | Early Clinical | Late Clinical | Milestone/Issue |
|---|---|---|---|---|---|---|---|---|
| Active | BAB-104 | MSTO, GBM |  |
IND in 4Q 2023 | ||||
| BAB-107 | mCRC |  |
in Vivo tool 4Q 2022 | |||||
| BAB-201 | Fibrosis |  |
Collaboration | |||||
| BAB-202 | RA | |
Collaboration | |||||
| BAB-301 | Parkinson | |
Hit 2Q 2022 | |||||
| BAB-802 | Antibody |  |
Collaboration | |||||
| BAB-803 | Fibrosis |  |
Collaboration | |||||
| Basic Study |
BAB-103 | CRC, NSCLC | |
Properties improvement | ||||
| BAB-105 | Breast Cancer |  |
Collaboration | |||||
| BAB-106 | Cancer metastasis |  |
Collaboration | |||||
| Undisclosed | immuno Oncology | |
structure 1Q 2022 | |||||
| Undisclosed | Fibrosis | |
structure 2Q 2022 |